Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
2023 · New England Journal of Medicine · 314 citations
https://doi.org/10.1056/nejmoa2211644
A
Annette von Drygalski
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
194
Papers
3.8K
Citations
30
h-index
74
i10-index
Annette von Drygalski is an academic researcher from UC San Diego Health System. The author has contributed to research in topics: Hemophilia Treatment and Research & Blood Coagulation and Thrombosis Mechanisms & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 30, co-authored 165 publications.
ORCID: 0000-0002-9426-6322Papers by this author
worksEfanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A
2023 · New England Journal of Medicine · 160 citations
https://doi.org/10.1056/nejmoa2209226
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
2019 · Blood Advances · 128 citations
https://doi.org/10.1182/bloodadvances.2019000811
Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
2022 · Blood Advances · 56 citations
https://doi.org/10.1182/bloodadvances.2022008886
Optimizing liver health before and after gene therapy for hemophilia A
2024 · Blood Advances · 14 citations
https://doi.org/10.1182/bloodadvances.2024013059
Consistency of serial ultrasonographic joint tissue measurements by the Joint tissueActivity and Damage Exam (JADE) protocol in relation to hemophilic joint health parameters
2023 · BMC Musculoskeletal Disorders · 5 citations
https://doi.org/10.1186/s12891-023-06419-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat